Back to Search Start Over

Nigrostriatal 6-hydroxydopamine lesions increase alpha-synuclein levels and permeability in rat colon.

Authors :
Cui H
Elford JD
Alitalo O
Perez-Pardo P
Tampio J
Huttunen KM
Kraneveld A
Forsberg MM
Myöhänen TT
Jalkanen AJ
Source :
Neurobiology of aging [Neurobiol Aging] 2023 Sep; Vol. 129, pp. 62-71. Date of Electronic Publication: 2023 May 07.
Publication Year :
2023

Abstract

Increasing evidence suggests that the gut-brain axis plays a crucial role in Parkinson's disease (PD). The abnormal accumulation of aggregated alpha-synuclein (aSyn) in the brain is a key pathological feature of PD. Intracerebral 6-hydroxydopamine (6-OHDA) is a widely used dopaminergic lesion model of PD. It exerts no aSyn pathology in the brain, but changes in the gut have not been assessed. Here, 6-OHDA was administered unilaterally either to the rat medial forebrain bundle (MFB) or striatum. Increased levels of glial fibrillary acidic protein in the ileum and colon were detected at 5 weeks postlesion. 6-OHDA decreased the Zonula occludens protein 1 barrier integrity score, suggesting increased colonic permeability. The total aSyn and Ser129 phosphorylated aSyn levels were elevated in the colon after the MFB lesion. Both lesions generally increased the total aSyn, pS129 aSyn, and ionized calcium-binding adapter molecule 1 (Iba1) levels in the lesioned striatum. In conclusion, 6-OHDA-induced nigrostriatal dopaminergic damage leads to increased aSyn levels and glial cell activation particularly in the colon, suggesting that the gut-brain axis interactions in PD are bidirectional and the detrimental process may start in the brain.<br />Competing Interests: Disclosure statement The authors declare no conflicts of interest.<br /> (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1558-1497
Volume :
129
Database :
MEDLINE
Journal :
Neurobiology of aging
Publication Type :
Academic Journal
Accession number :
37271045
Full Text :
https://doi.org/10.1016/j.neurobiolaging.2023.05.007